The September 15 short interest data have been compared with the previous report, and short interest moves were upward across most of these selected biotech stocks.
We liked the list of Buy-rated stocks in a recent Jefferies research piece, as they are all good stealth plays. That is, they are top companies, under the radar, that have a…
The August 31 short interest data have been compared with the previous report, and short interest decreased for most of these selected biotech stocks.
The top analyst upgrades, downgrades and initiations seen on Monday morning include Colgate-Palmolive, Gilead Sciences, Navistar, Occidental Petroleum, Pandora Media and Wal-Mart.
These are the top 24/7 Wall St. blue chip upgrades, downgrades and initiations tracked for the week of September 9.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Biogen, Broadcom, Devon Energy, Gilead Sciences, Mondelez and Urban Outfitters.
September 2, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Friday’s session. NYSE advancers led decliners by nearly 4 to 1 and…
September 1, 2016: Here are four stocks trading with relatively heavy volume among 39 equities making new 52-week lows in Thursday’s session. NYSE decliners led advancers by about 5 to 4 and…
August 31, 2016: Here are four stocks trading with relatively heavy volume among 27 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 3 to 2 and Nasdaq…
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Abercrombie & Fitch, Alibaba, Baidu, First Data, Marvell Technology and Under Armour.
August 29, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. NYSE advancers led decliners by about 7 to 3 and…
The August 15 short interest data have been compared with the previous report, and short interest moves were mixed across these selected biotech stocks.
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what…
Investors are now focusing on fundamentals and near-term catalysts that could provide a tailwind for some of the biotech leaders.
The short interest data are out for the July 29 settlement date and short interest decreased across these selected biotech stocks.
